Revelation Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Revelation Biosciences Inc 's ROA in the second quarter of 2026?
Revelation Biosciences Inc recorded a cumulative net loss of $-19 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -147.76%.

However, within the Healthcare sector 807 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4476, from total ROA ranking in the first quarter of 2026 at 5146.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	131.65 %	278.92 %	74.91 %	90.74 %	-56.03 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-19	-22	-15	-14	-12
Return On Assets (TTM)	-147.76 %	-191.67 %	-175.89 %	-195.26 %	-204.94 %
REVB's Total Ranking	# 4476	# 5146	# 4591	# 4683	# 4742
Total Assets (TTM) in million	12	15	12	13	5
Seq. Total Assets Change	-16.93 %	29.88 %	-9.9 %	138.3 %	35.89 %
Seq. Net Income Change	-	-	-	-	-

REVB's 5 Years Annual ROA >> Back to REVB Management Effectiveness >> Compare REVB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 380
Sector	# 808
Overall	# 4353

Return On Assets Statistics
High	Average	Low
22.64 %	-104.71 %	-204.94 %
(Mar 31 2023)		(Jun 30 2025)

News about Revelation Biosciences Inc Return on Assets ROA

Revelation Biosciences Gemini IND Accepted by FDA Amidst Competitive Revenue Struggles

Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences company focused on leveraging trained immunity for the treatment of various diseases, recently announced a significant milestone with the acceptance of its investigational new drug (IND) application for Gemini by the United States Food and Drug Administration (FDA). This acceptance enables the company to launch its Phase 1b clinical study in the U.S. marking a critical step in its ongoing research efforts to develop novel therapeutic approaches.The Gemini program aims to explore the effects and potential applications of trained immunity. Trained immunity refers to the enhanced response of the innate immune system to subsequent infections or diseases following an initial stimulus. Revelation’s development efforts in this area are aligned with the increasing interest in immunomodulatory therapies that harness the body’s natural defense mechanisms.

Financial Statements
Revelation Biosciences Inc 's Assets	$ 12 million	REVB's Balance sheet
Revelation Biosciences Inc 's Income	$ -3 million	Quarterly REVB's Income Statement
REVB's Income by Division		See REVB's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	74.91 %	-45.78 %	121.91 %	-88.55 %	5649.54 %
Total Assets in million	12	7	12	6	48
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-15	-15	0	-11	-2
Annual Return On Assets	-128.34 %	-227.1 %	-0.98 %	-196.78 %	-4.43 %

REVB's 5 Years Annual ROA >> Back to REVB Management Effectiveness >> Compare REVB ROA to its Competitors

More Return On Assets Ratios
REVB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
REVB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for REVB's Competitors
Subscribers only: Roa for Revelation Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for REVB's Customers

You may also want to know
REVB's Roi	REVB's Inventory Turnover Ratio	REVB's Growth Rates	REVB's Dividend Comparisons
	REVB's Profitability Ratios	REVB's Asset Turnover Ratio	REVB's Dividend Growth
REVB's Roe	REVB's Valuation Ratios	REVB's Financial Strength Ratios	REVB's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:24:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.